Loading company…
Precogify Pharmaceutical China is a Beijing company offering mass spectrometry-based cancer risk assessment models.
Founded in 2016 and based in Beijing, China, Precogify Pharmaceutical China Co., Ltd., also known as Zhongjing Pukang, provides cancer risk assessment models and early tumor screening services, including for colorectal and gastrointestinal tumors. It uses mass spectrometry and its B-GPS disease mechanism data discovery technology for metabolomic testing. In April 2018 it closed angel funding from Taiyu Investment, and in February 2022 it raised Series A funding led by Ourui Hongrun Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in